Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures

Launched by ONO PHARMACEUTICAL CO. LTD · Sep 8, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the long-term safety and tolerability of a medication called cenobamate in Japanese patients who experience partial onset seizures, a type of epilepsy. The trial is currently recruiting participants, and it aims to gather information on how well cenobamate can be tolerated over time in people who have already taken part in a previous study.

To be eligible for this trial, participants must have completed an earlier study (referred to as YKP3089C035) and cannot have stopped participating in that study for any reason. Additionally, if there have been significant changes to their health since that study, they may not be allowed to join. Those who participate can expect regular check-ins to monitor their health and how they respond to the medication. Overall, this trial is important because it seeks to ensure that cenobamate is safe for long-term use in individuals with partial seizures.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects completed Study YKP3089C035 by SK Life Science.
• Exclusion Criteria:
• • Subjects that have previously discontinued for any reason from the Core study (YKP3089C035).
• • Any significant changes to the medical history of the subject that in the opinion of the investigator, could affect the safety of the subject.